HYTN Secures Health Canada Drug Licence to Propel Cannabinoid Prescription Drug Pathway

LOS ANGELES- Vancouver-based HYTN Innovations Inc. (CSE: HYTN; OTC Pink: HYTNF) announced on July 14, 2025, that it has been granted a Cannabis Drug Licence (CDL) by Health Canada, effective July 2. This licence enhances HYTN’s existing Drug Establishment Licence (DEL) and federal cannabis licences, placing it among a select number of Canadian firms authorized to manufacture cannabis-derived pharmaceutical drugs. Already operating under Good Manufacturing Practices (GMP), HYTN now gains a regulated pathway to produce, package, label, and distribute prescription cannabinoid medicines, support clinical trials, generate regulatory data, and pursue future drug approvals.

The CDL bolsters HYTN’s capacity to serve both the regulated cannabis market and the global pharmaceutical sector. Key strategic developments include export-ready GMP manufacturing compliant with standards in the U.K., EU, and Australia; advancement toward EudraGMDP registration to participate in European pharmaceutical supply chains as an active pharmaceutical ingredient (API) and finished dose manufacturer; and strengthened position as a CDMO partner for biotech and pharmaceutical developers.

HYTN joins a limited group of manufacturers providing GMP-compliant cannabinoid APIs and finished drug products—an area that remains constrained due to regulatory complexity. The broader industry’s validation of prescription-grade cannabinoids is exemplified by Epidiolex, a cannabidiol-based treatment for seizure disorders, which recorded sales of $972.4 million in 2024 with an 88 percent gross margin